Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Avance | Success Rates in Biotech - Going The Wrong Way

Success Rates in Biotech - Going The Wrong Way

The report "Success Rates in Biotech - Going The Wrong Way" summarizes our review of 211 public biotech companies comprising over 1,500 drug development projects

1 Introduction................4

1.1 Why a study on success rates of biotech companies?...........4

1.2 What are success rates?....4

1.3 The role of success rates ...5

1.4 Are success rates of biotech companies different?...5

2 Methods.........7

2.1 Origin of Data ........7

2.2 Difference between FDA and EMEA ............7

2.3 Time frame ............7

2.4 Success rates per molecule vs. success rates per indication 8

2.5 When does a project count as a success?...8

2.6 Companies of the sample...8

3 Results.........11

3.1 Reporting of success and failure ...11

3.2 Distribution of sample over disease groups ............11

3.3 Overall biotech success rates (IND to approval) .....12

3.4 Disease group specific overall success rates (IND to approval) .......13

3.5 Number of projects in different disease groups .......14

3.6 Approvals by EMEA and FDA .......14

3.7 Disease group specific Success Rates ......15

3.7.1 Cancer (481 projects).15

3.7.2 Neurology......16

3.7.3 Infectious (131 projects)..........17

3.7.4 Inflammation (148 projects).....17

3.7.5 Cardiovascular (76 projects) ...18

3.7.6 Autoimmune (42 projects) .......19

3.7.7 Hematology (30 projects) ........20

3.7.8 Dermatology (27 projects).......20

3.7.9 Endocrinology (49 projects) ....21

3.7.10 Metabolic (71 projects) ..........21

3.7.11 Genitourinary (30 projects)....22

3.7.12 Musculoskeletal (29 projects)23

3.7.13 Gastrointestinal (22 projects) 24

4 Discussion ..25

4.1 Success Rates in Biotech (Avance) and Pharma (Kola, Landis) ......25

4.2 Difference in cancer..........30

4.3 Difference in Neurology ....31

4.4 Difference in Infectious Diseases ..32

4.5 Difference in Inflammation33

4.6 Difference in Cardiovascular .........34

4.7 Biotech has more late stage failures ..........34

4.8 Case Study: Arpida...........36

4.9 Biotech does not abandon low potential drugs........37

5 Conclusion ..38

List of figures & tables

Figure 1: Spreading of projects on different disease groups 11

Figure 2: Overall success rates phase 1 to approval (disease group unspecific). .....13

Figure 3: Success rates Phase I to Approval per disease group .....14

Figure 4: Success rates FDA vs EMEA ....15

Figure 5: Success rates in Cancer ............16

Figure 6: Success rates in Neurology .......16

Figure 7: Success rates in Infectious disease........17

Figure 8: Success rates in Inflammation ...18

Figure 9: Success rates in Cardiovascular18

Figure 10: Success rates in Autoimmune .19

Figure 11: Success rates in Hematology ..20

Figure 12: Success rates in Dermatology .20

Figure 13: Success rates in Endocrinology............21

Figure 14: Success rates in Metabolic disease......22

Figure 15: Success rates in Genitourinary disease22

Figure 16: Success rates in Musculoskeletal .........23

Figure 17: Success rate in Gastrointestinal ...........24

Figure 18: Overall success rate of all clinical projects over all disease groups. .......26

Figure 19: Success rate by phase of development and overall therapeutic areas. ...27

Figure 20: Probability to reach market for biotech and Pharma (Kola Landis)...........27

Figure 21: DiMasi Overall disease groups compared to Kola and Avance ...29

Figure 22: Success rates Cancer; Kola - Avance..30

Figure 23: DiMasi Cancer compared to Kola and Avance ..31

Figure 24: Success rates Neurology; Kola - Avance..........32

Figure 25: Success rates Infectious, Kola - Avance...........32

Figure 26: Success rates Inflammation, Kola - Avance......33

Figure 27: Success rates Cardiovascular, Kola - Avance ...34

Table 1: List of reviewed biotech companies (publicily traded)……………..…………10

Table 2: Projects in different disease groups and their overall success rates. ..........12

Table 3: Average clinical R&D spendings for one drug for biotech and Pharma. ......28

Table 4: Capitalized costs per commercialized drug...........29

January 2009
Table of Contents (PDF)
Price: $1,370.00 / €916.53

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions